Literature DB >> 24532139

Engrailed-2 is down-regulated but also ectopically expressed in clear cell renal cell carcinoma.

Cai-yong Lai1, Bin Pan, Yun Luo, Wei-bo Liang, Jie Chen, Dong-ming Ye, Ji-Nan Guo, Li Li, Ze-xuan Su.   

Abstract

Engrailed-2 (EN2), a member of the homeobox family of genes, encodes a homeodomain-containing transcription factor that is thought to be a potential oncogene in a number of cancers. Because the role of EN2 in clear cell renal cell carcinoma (CCRCC) has not been determined, we investigated its expression in CCRCC tissues and cell lines. Using immunohistochemical (IHC) staining, we found that EN2 protein was expressed in normal renal cells and tubules, but was frequently down-regulated in tissues from patients with CCRCC and in CCRCC cell lines. In addition, we found that EN2, which functions in the nucleus, was completely localized to the cytoplasm of CCRCC cells as detected by IHC and immunofluorescence staining. Furthermore, expression of EN2 protein was negatively correlated with increasing histological grade of CCRCC tumors (P = 0.003). The exact role of EN2 expression in renal carcinoma carcinogenesis requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532139     DOI: 10.1007/s11033-014-3229-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  20 in total

Review 1.  Wnt signaling and cancer.

Authors:  P Polakis
Journal:  Genes Dev       Date:  2000-08-01       Impact factor: 11.361

Review 2.  Immunotherapy for metastatic renal cell carcinoma.

Authors:  David F McDermott; Brian I Rini
Journal:  BJU Int       Date:  2007-05       Impact factor: 5.588

3.  Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein.

Authors:  A Joliot; A Maizel; D Rosenberg; A Trembleau; S Dupas; M Volovitch; A Prochiantz
Journal:  Curr Biol       Date:  1998-07-16       Impact factor: 10.834

Review 4.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

Review 5.  Treatment selection in metastatic renal cell carcinoma: expert consensus.

Authors:  Bernard Escudier; Cezary Szczylik; Camillo Porta; Martin Gore
Journal:  Nat Rev Clin Oncol       Date:  2012-04-10       Impact factor: 66.675

6.  Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer.

Authors:  Richard Morgan; Angela Boxall; Aagna Bhatt; Michael Bailey; Richard Hindley; Stephen Langley; Hayley C Whitaker; David E Neal; Mohammed Ismail; Hamish Whitaker; Nicola Annels; Agnieszka Michael; Hardev Pandha
Journal:  Clin Cancer Res       Date:  2011-03-01       Impact factor: 12.531

7.  The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell.

Authors:  M Hart; J P Concordet; I Lassot; I Albert; R del los Santos; H Durand; C Perret; B Rubinfeld; F Margottin; R Benarous; P Polakis
Journal:  Curr Biol       Date:  1999-02-25       Impact factor: 10.834

Review 8.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

9.  Proteomic profiling in pancreatic cancer with and without lymph node metastasis.

Authors:  Yazhou Cui; Jianmei Wu; Meijuan Zong; Guanhua Song; Qing Jia; Jinbo Jiang; Jinxiang Han
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

10.  Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.

Authors:  Hardev Pandha; Karen D Sorensen; Thorsten F Orntoft; Stephen Langley; Soren Hoyer; Michael Borre; Richard Morgan
Journal:  BJU Int       Date:  2012-05-15       Impact factor: 5.588

View more
  8 in total

1.  Hsa-miR-27b is up-regulated in cytomegalovirus-infected human glioma cells, targets engrailed-2 and inhibits its expression.

Authors:  Linqian Wang; Ming Yang; Shijing Liao; Wei Liu; Gan Dai; Guojun Wu; Liyu Chen
Journal:  Exp Biol Med (Maywood)       Date:  2017-03-26

Review 2.  Engrailed-2 might play an anti-oncogenic role in clear-cell renal cell carcinoma.

Authors:  Cai-Yong Lai; Yin Xu; Gan-Shen Yu; Xun Wu; Yun-Fei Li; Bin Pan; Bao-Li Heng; Yi-Jun Xue; Ze-Xuan Su
Journal:  J Mol Histol       Date:  2016-03-07       Impact factor: 2.611

3.  Engrailed-2 promoter hyper-methylation is associated with its downregulation in clear cell renal cell carcinoma.

Authors:  Cai-Yong Lai; Gan-Shen Yu; Yin Xu; Xun Wu; Bao-Li Heng; Yi-Jun Xue; Ze-Xuan Su
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

4.  Upregulation of centromere protein H is associated with progression of renal cell carcinoma.

Authors:  Xun Wu; Youcheng Lin; Liping Shi; Yi Huang; Caiyong Lai; Yongqiang Wang; Meng Zhang; Shupeng Wang; Baoli Heng; Ganshen Yu; Xinghua Du; Lu Fang; Yu Fu; Jie Chen; Zexiong Guo; Zexuan Su; Song Wu
Journal:  J Mol Histol       Date:  2015-08-07       Impact factor: 2.611

5.  Expression of engrailed homeobox 2 regulates the proliferation, migration and invasion of non-small cell lung cancer cells.

Authors:  Xiangxiao Lin; Xincun Liu; Cunqi Gong
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

6.  A novel protein is lower expressed in renal cell carcinoma.

Authors:  Ruili Guan; Yongde Xu; Hongen Lei; Zhezhu Gao; Zhongcheng Xin; Yinglu Guo
Journal:  Int J Mol Sci       Date:  2014-04-29       Impact factor: 5.923

7.  Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide.

Authors:  Tengfei Li; Wanchun Yang; Mao Li; Shuxin Zhang; Xingwang Zhou; Mingrong Zuo; Qiuyun Yuan; Mina Chen; Yanhui Liu
Journal:  Cancer Cell Int       Date:  2020-03-02       Impact factor: 5.722

8.  Circular RNA circ_0000467 regulates colorectal cancer development via miR-382-5p/EN2 axis.

Authors:  Lu Xie; Zhihong Pan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.